A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
Identifieur interne : 008F13 ( Main/Exploration ); précédent : 008F12; suivant : 008F14A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
Auteurs : P. A. Vasey [Royaume-Uni, Australie] ; M. Gore [Royaume-Uni] ; R. Wilson [Royaume-Uni] ; G. Rustin [Royaume-Uni] ; H. Gabra [Royaume-Uni] ; J-P. Guastalla [France] ; E. P. Lauraine [France] ; J. Paul [Royaume-Uni] ; K. Carty [Royaume-Uni] ; S. Kaye [Royaume-Uni]Source :
- British journal of cancer [ 0007-0920 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m-2) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day-1 (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day-1 (cohort 2b; the erlotinib dose was escalated to 100mg day-1 in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day-1, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 003459
- to stream PascalFrancis, to step Curation: 002B90
- to stream PascalFrancis, to step Checkpoint: 003451
- to stream Main, to step Merge: 009865
- to stream Pmc, to step Corpus: 000022
- to stream Pmc, to step Curation: 000022
- to stream Pmc, to step Checkpoint: 002A55
- to stream Ncbi, to step Merge: 000395
- to stream Ncbi, to step Curation: 000395
- to stream Ncbi, to step Checkpoint: 000395
- to stream Main, to step Merge: 008E92
- to stream Main, to step Curation: 008F13
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers</title>
<author><name sortKey="Vasey, P A" sort="Vasey, P A" uniqKey="Vasey P" first="P. A." last="Vasey">P. A. Vasey</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow, Scotland GI 1 6NT</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Medicine, University of Queensland</s1>
<s2>Brisbane Q4029</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Brisbane Q4029</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gore, M" sort="Gore, M" uniqKey="Gore M" first="M." last="Gore">M. Gore</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Royal Marsden Hospital, Fulham Road</s1>
<s2>London SW15 3SW</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SW15 3SW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wilson, R" sort="Wilson, R" uniqKey="Wilson R" first="R." last="Wilson">R. Wilson</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Belfast City Hospital, Lisbum Road</s1>
<s2>Belfast, Ireland BT9 7AB</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Belfast, Ireland BT9 7AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rustin, G" sort="Rustin, G" uniqKey="Rustin G" first="G." last="Rustin">G. Rustin</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mount Vernon Hospital, Rickmansworth Road</s1>
<s2>Northwood, Hertfordshire HA6 2RN</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Northwood, Hertfordshire HA6 2RN</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gabra, H" sort="Gabra, H" uniqKey="Gabra H" first="H." last="Gabra">H. Gabra</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Western General Hospital, Crewe Road South</s1>
<s2>Edinburgh, Scotland EH4 2XU</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Edinburgh, Scotland EH4 2XU</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J-P." last="Guastalla">J-P. Guastalla</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Centre Léon-Bérard, rue Laennec</s1>
<s2>69373, Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lauraine, E P" sort="Lauraine, E P" uniqKey="Lauraine E" first="E. P." last="Lauraine">E. P. Lauraine</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame</s1>
<s2>75181 Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>75181 Paris</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Paul, J" sort="Paul, J" uniqKey="Paul J" first="J." last="Paul">J. Paul</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow, Scotland GI 1 6NT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Carty, K" sort="Carty, K" uniqKey="Carty K" first="K." last="Carty">K. Carty</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow, Scotland GI 1 6NT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Royal Marsden Hospital, Downs Road</s1>
<s2>Sutton, Surrey SM2 5PT</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Sutton, Surrey SM2 5PT</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0315574</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0315574 INIST</idno>
<idno type="RBID">Pascal:08-0315574</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003459</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002B90</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003451</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003451</idno>
<idno type="wicri:doubleKey">0007-0920:2008:Vasey P:a:phase:ib</idno>
<idno type="wicri:Area/Main/Merge">009865</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410113</idno>
<idno type="RBID">PMC:2410113</idno>
<idno type="wicri:Area/Pmc/Corpus">000022</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000022</idno>
<idno type="wicri:Area/Pmc/Curation">000022</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000022</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002A55</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002A55</idno>
<idno type="wicri:Area/Ncbi/Merge">000395</idno>
<idno type="wicri:Area/Ncbi/Curation">000395</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000395</idno>
<idno type="wicri:doubleKey">0007-0920:2008:Vasey P:a:phase:ib</idno>
<idno type="wicri:Area/Main/Merge">008E92</idno>
<idno type="wicri:Area/Main/Curation">008F13</idno>
<idno type="wicri:Area/Main/Exploration">008F13</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers</title>
<author><name sortKey="Vasey, P A" sort="Vasey, P A" uniqKey="Vasey P" first="P. A." last="Vasey">P. A. Vasey</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow, Scotland GI 1 6NT</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Medicine, University of Queensland</s1>
<s2>Brisbane Q4029</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Brisbane Q4029</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gore, M" sort="Gore, M" uniqKey="Gore M" first="M." last="Gore">M. Gore</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Royal Marsden Hospital, Fulham Road</s1>
<s2>London SW15 3SW</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SW15 3SW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wilson, R" sort="Wilson, R" uniqKey="Wilson R" first="R." last="Wilson">R. Wilson</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Belfast City Hospital, Lisbum Road</s1>
<s2>Belfast, Ireland BT9 7AB</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Belfast, Ireland BT9 7AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rustin, G" sort="Rustin, G" uniqKey="Rustin G" first="G." last="Rustin">G. Rustin</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mount Vernon Hospital, Rickmansworth Road</s1>
<s2>Northwood, Hertfordshire HA6 2RN</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Northwood, Hertfordshire HA6 2RN</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gabra, H" sort="Gabra, H" uniqKey="Gabra H" first="H." last="Gabra">H. Gabra</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Western General Hospital, Crewe Road South</s1>
<s2>Edinburgh, Scotland EH4 2XU</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Edinburgh, Scotland EH4 2XU</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J-P." last="Guastalla">J-P. Guastalla</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Centre Léon-Bérard, rue Laennec</s1>
<s2>69373, Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lauraine, E P" sort="Lauraine, E P" uniqKey="Lauraine E" first="E. P." last="Lauraine">E. P. Lauraine</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame</s1>
<s2>75181 Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>75181 Paris</wicri:noRegion>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Paul, J" sort="Paul, J" uniqKey="Paul J" first="J." last="Paul">J. Paul</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow, Scotland GI 1 6NT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Carty, K" sort="Carty, K" uniqKey="Carty K" first="K." last="Carty">K. Carty</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1>
<s2>Glasgow, Scotland GI 1 6NT</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow, Scotland GI 1 6NT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Royal Marsden Hospital, Downs Road</s1>
<s2>Sutton, Surrey SM2 5PT</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Sutton, Surrey SM2 5PT</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">British journal of cancer</title>
<title level="j" type="abbreviated">Br. J. cancer</title>
<idno type="ISSN">0007-0920</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">British journal of cancer</title>
<title level="j" type="abbreviated">Br. J. cancer</title>
<idno type="ISSN">0007-0920</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Cancerology</term>
<term>Carboplatin</term>
<term>Clinical trial</term>
<term>Docetaxel</term>
<term>Epidermal growth factor receptor</term>
<term>Erlotinib</term>
<term>Fallopian tube cancer</term>
<term>Malignant tumor</term>
<term>Ovary</term>
<term>Peritoneum</term>
<term>Primary</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Docétaxel</term>
<term>Essai clinique</term>
<term>Ovaire</term>
<term>Carboplatine</term>
<term>Primaire</term>
<term>Péritoine</term>
<term>Erlotinib</term>
<term>Récepteur facteur croissance épiderme</term>
<term>Cancérologie</term>
<term>Cancer de la trompe de Fallope</term>
<term>Tumeur maligne</term>
<term>Anticancéreux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m<sup>-2</sup>
) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day<sup>-1</sup>
(cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day<sup>-1</sup>
(cohort 2b; the erlotinib dose was escalated to 100mg day<sup>-1</sup>
in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day<sup>-1</sup>
, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Royaume-Uni</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Rhône-Alpes</li>
<li>Île-de-France</li>
</region>
<settlement><li>Lyon</li>
<li>Paris</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Vasey, P A" sort="Vasey, P A" uniqKey="Vasey P" first="P. A." last="Vasey">P. A. Vasey</name>
</noRegion>
<name sortKey="Carty, K" sort="Carty, K" uniqKey="Carty K" first="K." last="Carty">K. Carty</name>
<name sortKey="Gabra, H" sort="Gabra, H" uniqKey="Gabra H" first="H." last="Gabra">H. Gabra</name>
<name sortKey="Gore, M" sort="Gore, M" uniqKey="Gore M" first="M." last="Gore">M. Gore</name>
<name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name>
<name sortKey="Paul, J" sort="Paul, J" uniqKey="Paul J" first="J." last="Paul">J. Paul</name>
<name sortKey="Rustin, G" sort="Rustin, G" uniqKey="Rustin G" first="G." last="Rustin">G. Rustin</name>
<name sortKey="Wilson, R" sort="Wilson, R" uniqKey="Wilson R" first="R." last="Wilson">R. Wilson</name>
</country>
<country name="Australie"><noRegion><name sortKey="Vasey, P A" sort="Vasey, P A" uniqKey="Vasey P" first="P. A." last="Vasey">P. A. Vasey</name>
</noRegion>
</country>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J-P." last="Guastalla">J-P. Guastalla</name>
</region>
<name sortKey="Lauraine, E P" sort="Lauraine, E P" uniqKey="Lauraine E" first="E. P." last="Lauraine">E. P. Lauraine</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008F13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008F13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:08-0315574 |texte= A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |